Incyte Launches Xatilimab, Retifanlimab in Asia-Pacific
This is a news story, published by Yahoo Finance, that relates primarily to Minjuvi news.
Minjuvi news
For more Minjuvi news, you can click here:
more Minjuvi newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
new therapies axatilimab. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Incyte news, axatilimab news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
oncology portfolioTipRanks
•Health
Health
Specialised Therapeutics announces expanded partnership with Incyte

85% Informative
Specialised Therapeutics announced the expansion of its existing supply and distribution agreement with Incyte (INCY) Biosciences International Sarl.
The expanded agreement will see new therapies axatilimab and retifanlimab added to the current partnered portfolio of Minjuvi and Pemazyre .
VR Score
77
Informative language
74
Neutral language
48
Article tone
formal
Language
English
Language complexity
98
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
11
Source diversity
2
Affiliate links
no affiliate links